MedTrace Logo

Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease

NCT02742909 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-10-01

No results posted yet for this study

Summary

To evaluate the acute effect of recombinant human brain natriuretic peptide(rhBNP) on pulmonary hypertension of acute exacerbations of chronic pulmonary disease. rhBNP was administered as a continuous infusion for 24 hours , pulmonary artery pressure and other hemodynamic parameters were monitored by Swan- Ganz catheter.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

rhBNP

rhBNP was administered as a continuous infusion for 24 hours before or after placebo

DRUG

placebo

normal saline as a placebo was administered as a continuous infusion for 24 hours

Sponsors & Collaborators

  • LI ZHAO

    lead OTHER

Principal Investigators

  • LI ZHAO, DOCTOR · SHENJING HOSPTIAL OF CHINA MEDICAL UNIVERSITY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742909 on ClinicalTrials.gov